Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-05-01
DOI
10.1111/hepr.13358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
- (2018) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice
- (2018) Shinsuke Uchikawa et al. HEPATOLOGY RESEARCH
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment
- (2018) Teiji Kuzuya et al. ONCOLOGY
- Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment
- (2018) Fabio Piscaglia et al. Liver Cancer
- Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Recent advances in medical management of hepatocellular carcinoma
- (2018) Kenji Ikeda HEPATOLOGY RESEARCH
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
- (2017) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives
- (2017) Masafumi Ikeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma
- (2016) Chloé Sauzay et al. CLINICA CHIMICA ACTA
- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
- (2016) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2016) Teiji Kuzuya et al. ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma
- (2015) Teiji Kuzuya et al. PLoS One
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started